These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12916558)

  • 1. Comparison of different risk factors that result in endothelial damage leading to diabetic microangiopathy.
    Kayacan SM; Kazancioğlu R; Oflaz H; Tuna S
    South Med J; 2003 Apr; 96(4):387-90. PubMed ID: 12916558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Von Willebrand factor in diabetic angiopathy.
    Kessler L; Wiesel ML; Attali P; Mossard JM; Cazenave JP; Pinget M
    Diabetes Metab; 1998 Sep; 24(4):327-36. PubMed ID: 9805643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Profile of the main risk factors of arteriosclerosis in patients with diabetes mellitus].
    Tatoń J; Walewski J
    Pol Tyg Lek; 1992 Jan 6-13; 47(1-2):3-7. PubMed ID: 1409038
    [No Abstract]   [Full Text] [Related]  

  • 4. Endothelial dysfunction: its relationship with acute hyperglycaemia and hyperlipidemia.
    Lee IK; Kim HS; Bae JH
    Int J Clin Pract Suppl; 2002 Jul; (129):59-64. PubMed ID: 12166609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Manipulating the vascular biology of coronary atherosclerosis in diabetes: new opportunities.
    Orford JL; Kinlay S; Fernandes J; Behrendt D; Ganz P; Selwyn AP
    J Lab Clin Med; 2001 Feb; 137(2):82-92. PubMed ID: 11174464
    [No Abstract]   [Full Text] [Related]  

  • 6. [Environmental factors as the risk factors for diabetic complications].
    Hashimoto N; Saito Y
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():102-7. PubMed ID: 12430214
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cerebrovascular disorders of diabetic complications].
    Udaka F; Fushimi H; Kameyama M
    Nihon Rinsho; 1991 Feb; 49 Suppl():85-91. PubMed ID: 2033882
    [No Abstract]   [Full Text] [Related]  

  • 8. Alterations of von Willebrand factor and ristocetin cofactor activity during atrial fibrillation.
    Kalyoncu U; Dizdar O; Erkan Duman A; Karadag O; Tufan A; Yucel O; Tayfur O; Sen D; Ulger Z; Kepez A; Kocabas U; Haznedaroglu I
    Clin Appl Thromb Hemost; 2009 Feb; 15(1):103-8. PubMed ID: 18160605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. von Willebrand factor and endothelial damage in essential hypertension.
    Blann AD; Naqvi T; Waite M; McCollum CN
    J Hum Hypertens; 1993 Apr; 7(2):107-11. PubMed ID: 8510081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognosis of diabetic microangiopathy].
    Yamasaki Y
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():32-6. PubMed ID: 15999682
    [No Abstract]   [Full Text] [Related]  

  • 11. Von Willebrand factor in type 1 diabetes: its production and coronary artery calcification.
    Chan NN; Fuller JH; Rubens M; Colhoun HM
    Med Sci Monit; 2003 Jul; 9(7):CR297-303. PubMed ID: 12883448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative and qualitative assessment of plasma von Willebrand factor variations, as induced by forearm venous stasis in patients with diabetic microangiopathy.
    Porta M; Ricchetti I; La Selva M; Bertagna A; Molinatti GM
    Diabetes Res; 1984 Nov; 1(4):219-21. PubMed ID: 6442228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: implications for atherogenesis? A preliminary report.
    Lip GY; Blann AD; Zarifis J; Beevers M; Lip PL; Beevers DG
    J Hypertens; 1995 Dec; 13(12 Pt 2):1674-8. PubMed ID: 8903631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of peripheral arterial obstructive disease related factors among diabetic population aged > or = 50].
    Guan H; Liu ZM; Li GW; Guo XH; Xu ZR; Zou DJ; Xing HL; Liu W; Sheng ZY; Tian HM; Zhu DL; Yu DM; Zhuang WT; Chen LL; Weng JP
    Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(1):23-7. PubMed ID: 17403307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Incidence of hyperlipemia, hyperuricemia, diabetes mellitus, hypertension and overweight in arterial obliterating disease].
    Wollenweber J; Doenecke P; Greten H; Hild R; Nobbe F; Schmidt FH; Wagner E
    Dtsch Med Wochenschr; 1971 Jan; 96(3):103-7. PubMed ID: 5539511
    [No Abstract]   [Full Text] [Related]  

  • 16. Normalisation of tissue factor pathway inhibitor activity after glycaemic control optimisation in type 1 diabetic patients.
    Rigla M; Mateo J; Fontcuberta J; Souto JC; de Leiva A; Pérez A
    Thromb Haemost; 2000 Aug; 84(2):223-7. PubMed ID: 10959693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Arterial hypertension and diabetes in Ouagadougou (Burkina Faso)].
    Drabo PY; Guira O; Ouandaogo BJ; Kabore J
    Bull Soc Pathol Exot; 1996; 89(1):33-4. PubMed ID: 8765955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between uric acid and endothelial dysfunction predicts new onset of diabetes in hypertensive patients.
    Perticone F; Maio R; Tassone JE; Perticone M; Pascale A; Sciacqua A; Sesti G
    Int J Cardiol; 2013 Jul; 167(1):232-6. PubMed ID: 22245480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors.
    Hlubocká Z; Umnerová V; Heller S; Peleska J; Jindra A; Jáchymová M; Kvasnicka J; Horký K; Aschermann M
    J Hum Hypertens; 2002 Aug; 16(8):557-62. PubMed ID: 12149661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oxidative-antioxidative balance disturbance and risk factors as well as vascular complications in patients with diabetes type 2].
    Knapik-Kordecka M; Piwowar A; Warwas M
    Wiad Lek; 2007; 60(7-8):329-34. PubMed ID: 18175551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.